ArGEN-X BV has announced its intention to make an initial public offering of shares on the Euronext exchange in Brussels in order to support the development of its therapeutic antibody portfolio. Further details were not yet available. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
